Defendant
2 cases as defendant.
I'll research Natco Pharma to build an accurate profile.
Natco Pharma Limited (commonly "Natco"; NSE: NATCOPHARM, BSE: 524816) is a publicly listed Indian pharmaceutical company incorporated on 19 September 1981 and headquartered at Natco House, Banjara Hills, Hyderabad, Telangana. It is not a subsidiary. Recent filings put headcount around 4,200–5,000 employees, FY2025 revenue near ₹44 billion (roughly $500M), and market capitalization in the ₹17,500 crore (~$2.2B) range (BSE/NSE filings; StockAnalysis; MarketWatch).
Products / operations. Natco is a vertically integrated manufacturer of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs), with a smaller agrochemicals/crop-health segment. Its core focus is complex generics and niche molecules, particularly oncology (blood, liver, kidney, lung, breast, ovarian cancers), plus hepatitis-B/C, cardiology, diabetology, and CNS/pain-management APIs. It operates roughly nine manufacturing units and two R&D centers in India and sells in 50+ countries, exporting via subsidiaries in the US, Canada, Brazil, Singapore, and elsewhere. In the US it favors a partnership model in which local partners handle marketing and litigation, and it carries a pipeline of Paragraph IV / first-to-file ANDAs (Investor presentation; FY2023-24 annual report).
Litigation posture. This is an operating company defending itself, not a patent assertion entity. The tracked data shows 0 cases as plaintiff and 2 as defendant, both patent-infringement suits brought against it by a brand manufacturer in the District of New Jersey — a common Hatch-Waxman forum, not a plaintiff-friendly NPE venue.
Notable cases. Both tracked matters are Celgene Corporation v. Natco Pharma Limited (D.N.J., 2010 and 2012), concerning Natco's generic lenalidomide (Revlimid) ANDA and Celgene's compound, REMS, and polymorph patents. The parties settled in December 2015, with Celgene granting Natco a license to sell generic lenalidomide in the US (a volume-limited entry from March 2022, with unlimited quantity from 31 January 2026) (Reuters; generalcounselnews). Natco has since been referenced in follow-on antitrust litigation over those settlement terms, but has not been a plaintiff in the tracked patent suits.
Patent infringement action against Natco Pharma Limited asserting U.S. Patent No. 7,968,569. The Natco line of cases settled in December 2015 with volume-limited entry from March 2022 and unlimited entry from January 31, 2026.
Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.